HEALTH TECHNOLOGY ASSESSMENT (HTA)
The reimbursement landscape is constantly evolving. Requirements vary even between key markets and coordination is required across multiple areas to produce top-quality results. At IMAC we are a team of specialists with experts in health economics, real-world evidence (RWE) generation, and market access and outcomes strategy who have decades of experience producing successful submissions in over 28 countries and across a variety of therapeutic areas. As a boutique company, we integrate as part of your team to help you achieve the best result for your product!
IMAC specialists have direct industry and reimbursement agency experience in Europe and North America, and are positioned to help our clients with the most challenging situations. We have a deep knowledge and understanding of payer needs and requirements—in combination with our expertise in evidence generation and economic modeling—allows us to provide comprehensive strategic and technical support at every level.
IMAC has extensive experience leading global HTA launches and adapting HTA submissions to local markets. We also have considerable expertise in critiquing HTA submissions developed by manufacturers or outside vendors and advising on how to overcome challenges and improve messaging to ensure success.
IMAC provides universal support, developing all components of the reimbursement submission including:
- Development of a robust Value Story for your therapy that is carried through all the components of a submission,
- Targeted review of the natural history and burden of disease,
- Systematic review of clinical, utility, and economic literature (SLR),
- Network meta-analyses and indirect treatment comparisons to close evidence gaps (NMA and ITC),
- Utility research and resource use/cost estimation,
- Pre- and post-submission strategy to ensure the fastest, seamless path to the positive reimbursement of your therapy.
Some examples:
-
Development of HTA submissions for a first-in-class, orphan oncology product in over 16 countries in the UK, Europe, and North America, including to NICE, SMC, and CADTH.
-
Market access strategy and HTA submission for a major oncology project in 8 countries in the UK and Europe.
How can we help you?
Contact us at one of our International offices or submit a business inquiry online.
Yulia specializes in systematic literature reviews, pharmacoeconomic analyses, and outcomes research.
Looking for a first-class market access partner?